Parkinson disease (PD) is a complex neurodegenerative disorder with largely unknown genetic mechanisms. While the degeneration of dopaminergic neurons in PD mainly takes place in the substantia nigra pars compacta (SN) region, other brain areas, including the prefrontal cortex, develop Lewy bodies, the neuropathological hallmark of PD. We generated and analyzed expression data from the prefrontal cortex Brodmann Area 9 (BA9) of 27 PD and 26 control samples using the 44K One-Color Agilent 60-mer Whole Human Genome Microarray. All samples were male, without significant Alzheimer disease pathology and with extensive pathological annotation available. 507 of the 39,122 analyzed expression probes were different between PD and control samples at false discovery rate (FDR) of 5%. One of the genes with significantly increased expression in PD was the forkhead box O1 (FOXO1) transcription factor. Notably, genes carrying the FoxO1 binding site were significantly enriched in the FDR–significant group of genes (177 genes covered by 189 probes), suggesting a role for FoxO1 upstream of the observed expression changes. Single-nucleotide polymorphisms (SNPs) selected from a recent meta-analysis of PD genome-wide association studies (GWAS) were successfully genotyped in 50 out of the 53 microarray brains, allowing a targeted expression–SNP (eSNP) analysis for 52 SNPs associated with PD affection at genome-wide significance and the 189 probes from FoxO1 regulated genes. A significant association was observed between a SNP in the cyclin G associated kinase (GAK) gene and a probe in the spermine oxidase (SMOX) gene. Further examination of the FOXO1 region in a meta-analysis of six available GWAS showed two SNPs significantly associated with age at onset of PD. These results implicate FOXO1 as a PD–relevant gene and warrant further functional analyses of its transcriptional regulatory mechanisms.
Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118: 821–839.
[3]
Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, et al. (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2: 52ra73.
[4]
Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, et al. (2009) A cross-study transcriptional analysis of Parkinson's disease. PLoS ONE 4: e4955. doi:10.1371/journal.pone.0004955.
[5]
Edwards YJ, Beecham GW, Scott WK, Khuri S, Bademci G, et al. (2011) Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach. PLoS ONE 6: e16917. doi:10.1371/journal.pone.0016917.
[6]
Lanoue AC, Dumitriu A, Myers RH, Soghomonian JJ (2010) Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease. Exp Neurol 226: 207–217.
[7]
Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, et al. (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta neuropathologica 117: 613–634.
[8]
Pankratz N, Beecham GW, Destefano AL, Dawson TM, Doheny KF, et al. (2012) Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of neurology 71: 370–384.
[9]
Elstner M, Morris CM, Heim K, Bender A, Mehta D, et al. (2011) Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta neuropathologica 122: 75–86.
[10]
Simunovic F, Yi M, Wang Y, Macey L, Brown LT, et al. (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132: 1795–1809.
[11]
Zhang Y, James M, Middleton FA, Davis RL (2005) Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 137B: 5–16.
[12]
Mudo G, Makela J, Liberto VD, Tselykh TV, Olivieri M, et al. (2012) Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cellular and molecular life sciences : CMLS 69: 1153–1165.
[13]
Nuber S, Petrasch-Parwez E, Arias-Carrion O, Koch L, Kohl Z, et al. (2011) Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiology of disease 44: 192–204.
[14]
Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, et al. (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS ONE 5: e11464. doi:10.1371/journal.pone.0011464.
[15]
Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, et al. (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nature communications 3: 668.
[16]
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197–211.
[17]
Wakabayashi K, Tanji K, Mori F, Takahashi H (2007) The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27: 494–506.
[18]
Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593–605.
[19]
Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet 42: 781–785.
[20]
Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B (2011) Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet 75: 195–200.
[21]
Simon-Sanchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, et al. (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 19: 655–661.
[22]
Dumitriu A, Pacheco CD, Wilk JB, Strathearn KE, Latourelle JC, et al. (2010) Cyclin-G-associated kinase modifies alpha-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet 20: 1478–1487.
[23]
International Parkinson Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet 377: 641–649.
[24]
Cervelli M, Amendola R, Polticelli F, Mariottini P (2011) Spermine oxidase: ten years after. Amino Acids.
[25]
Kang SJ, Scott WK, Li YJ, Hauser MA, van der Walt JM, et al. (2006) Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson disease. Mov Disord 21: 2175–2180.
[26]
Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, et al. (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55: 533–538.
[27]
Nakatome M, Tun Z, Shimada S, Honda K (1998) Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease. Biochem Biophys Res Commun 247: 452–456.
[28]
Hotamisligil GS, Girmen AS, Fink JS, Tivol E, Shalish C, et al. (1994) Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 9: 305–310.
[29]
Heinzen EL, Ge D, Cronin KD, Maia JM, Shianna KV, et al. (2008) Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol 6: e1. doi:10.1371/journal.pbio.0060001.
[30]
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
[31]
Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, et al. (2009) FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc Natl Acad Sci U S A 106: 5153–5158.
[32]
Su B, Liu H, Wang X, Chen SG, Siedlak SL, et al. (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener 4: 32.
[33]
Koh H, Kim H, Kim MJ, Park J, Lee HJ, et al. (2012) Silent Information Regulator 2 (Sir2) and Forkhead box O (FOXO) Complement Mitochondrial Dysfunction and Dopaminergic Neuron Loss in Drosophila Pten-induced kinase 1 (PINK1) Null Mutant. The Journal of biological chemistry.
[34]
Kuwahara T, Tonegawa R, Ito G, Mitani S, Iwatsubo T (2012) Phosphorylation of alpha-synuclein at Ser129 reduces neuronal dysfunction by lowering its membrane-binding property in Caenorhabditis elegans. The Journal of biological chemistry.
[35]
Kanao T, Venderova K, Park DS, Unterman T, Lu B, et al. (2010) Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila. Hum Mol Genet 19: 3747–3758.
[36]
Kanao T, Sawada T, Davies SA, Ichinose H, Hasegawa K, et al. (2012) The Nitric Oxide-Cyclic GMP Pathway Regulates FoxO and Alters Dopaminergic Neuron Survival in Drosophila. PLoS ONE 7: e30958. doi:10.1371/journal.pone.0030958.
[37]
Shimamura M, Sato N, Morishita R (2011) Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Current gene therapy 11: 491–500.
[38]
Salehi Z, Rajaei F (2010) Expression of hepatocyte growth factor in the serum and cerebrospinal fluid of patients with Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 17: 1553–1556.
[39]
Tucci A, Nalls MA, Houlden H, Revesz T, Singleton AB, et al. (2010) Genetic variability at the PARK16 locus. European journal of human genetics : EJHG 18: 1356–1359.
[40]
Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature genetics 41: 1303–1307.
O'Keeffe GC, Tyers P, Aarsland D, Dalley JW, Barker RA, et al. (2009) Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proceedings of the National Academy of Sciences of the United States of America 106: 8754–8759.
[43]
Chi Y, Fan Y, He L, Liu W, Wen X, et al. (2011) Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease. Aging cell 10: 368–382.
[44]
Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, et al. (2011) Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proceedings of the National Academy of Sciences of the United States of America 108: 17004–17009.
[45]
Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987–2007. Cell and tissue banking 9: 229–245.
[46]
Kauffmann A, Gentleman R, Huber W (2009) arrayQualityMetrics–a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415–416.
[47]
Huang DW, Sherman BT, Lempicki RA (2008) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 4: 44–57.
[48]
Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1–13.
[49]
Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26: 2190–2191.
[50]
Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173–1182.
[51]
Jasti S, Dudley WN, Goldwater E (2008) SAS macros for testing statistical mediation in data with binary mediators or outcomes. Nurs Res 57: 118–122.
[52]
MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V (2002) A comparison of methods to test mediation and other intervening variable effects. Psychol Methods 7: 83–104.
[53]
Gao X, Starmer J, Martin ER (2008) A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 32: 361–369.
[54]
Sankoh AJ, Huque MF, Dubey SD (1997) Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16: 2529–2542.
[55]
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
[56]
Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, et al. (2009) Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet 84: 445–458.
[57]
Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, et al. (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77: 685–693.
[58]
Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, et al. (1995) The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200: 151–154.
